The associations of Positive and Negative Valence Systems, Cognitive Systems and Social Processes on disease severity in anxiety and depressive disorders.
RDoC
Research Domain Criteria
anxiety disoders
depression
disease severity
transdiagnostic
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
02
2023
accepted:
19
05
2023
medline:
3
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
epublish
Résumé
Anxiety and depressive disorders share common features of mood dysfunctions. This has stimulated interest in transdiagnostic dimensional research as proposed by the Research Domain Criteria (RDoC) approach by the National Institute of Mental Health (NIMH) aiming to improve the understanding of underlying disease mechanisms. The purpose of this study was to investigate the processing of RDoC domains in relation to disease severity in order to identify latent disorder-specific as well as transdiagnostic indicators of disease severity in patients with anxiety and depressive disorders. Within the German research network for mental disorders, 895 participants ( The results confirmed a transdiagnostic relationship for all four domains, as we found significant main effects on disease severity within domain-specific models (PVS: The cross-sectional study design prevents causal conclusions. Further limitations include possible outliers and heteroskedasticity in all regression models which we appropriately controlled for. Our key results show that symptom burden in anxiety and depressive disorders is associated with latent RDoC indicators in transdiagnostic and disease-specific ways.
Sections du résumé
Background
UNASSIGNED
Anxiety and depressive disorders share common features of mood dysfunctions. This has stimulated interest in transdiagnostic dimensional research as proposed by the Research Domain Criteria (RDoC) approach by the National Institute of Mental Health (NIMH) aiming to improve the understanding of underlying disease mechanisms. The purpose of this study was to investigate the processing of RDoC domains in relation to disease severity in order to identify latent disorder-specific as well as transdiagnostic indicators of disease severity in patients with anxiety and depressive disorders.
Methods
UNASSIGNED
Within the German research network for mental disorders, 895 participants (
Results
UNASSIGNED
The results confirmed a transdiagnostic relationship for all four domains, as we found significant main effects on disease severity within domain-specific models (PVS:
Limitations
UNASSIGNED
The cross-sectional study design prevents causal conclusions. Further limitations include possible outliers and heteroskedasticity in all regression models which we appropriately controlled for.
Conclusion
UNASSIGNED
Our key results show that symptom burden in anxiety and depressive disorders is associated with latent RDoC indicators in transdiagnostic and disease-specific ways.
Identifiants
pubmed: 37398596
doi: 10.3389/fpsyt.2023.1161097
pmc: PMC10313476
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1161097Informations de copyright
Copyright © 2023 Förstner, Böttger, Moldavski, Bajbouj, Pfennig, Manook, Ising, Pittig, Heinig, Heinz, Mathiak, Schulze, Schneider, Kamp-Becker, Meyer-Lindenberg, Padberg, Banaschewski, Bauer, Rupprecht, Wittchen, Rapp and Tschorn.
Déclaration de conflit d'intérêts
FP is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem, Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has received speaker’s honoraria from Mag&More GmbH, the neuroCare Group, Munich, Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc. TB served in an advisory or consultancy role for eye level, Infectopharm, Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Roche, and Takeda. He received conference support or speaker’s fee by Janssen, Medice and Takeda. He received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Biol Mood Anxiety Disord. 2011 Nov 07;1(1):10
pubmed: 22738433
Neurosci Biobehav Rev. 2013 Feb;37(2):152-63
pubmed: 23206667
J Abnorm Psychol. 1991 Aug;100(3):316-36
pubmed: 1918611
J Affect Disord. 2017 Jul;216:17-29
pubmed: 28131628
J Behav Ther Exp Psychiatry. 2013 Jun;44(2):262-70
pubmed: 23298819
J Abnorm Psychol. 1998 May;107(2):179-92
pubmed: 9604548
J Affect Disord. 2017 Jul;216:3-16
pubmed: 28237133
Neuropsychopharmacology. 2016 Jan;41(2):454-63
pubmed: 26068725
Depress Anxiety. 2014 Feb;31(2):150-9
pubmed: 23861215
Neurosci Biobehav Rev. 2016 Oct;69:313-32
pubmed: 27395342
J Clin Child Adolesc Psychol. 2021 Sep-Oct;50(5):609-618
pubmed: 31922427
Psychol Med. 2014 Jul;44(10):2029-40
pubmed: 24168753
Depress Anxiety. 2017 Jul;34(7):621-631
pubmed: 28453905
J Abnorm Psychol. 2013 Aug;122(3):645-55
pubmed: 23815396
Curr Opin Psychiatry. 2011 Jan;24(1):49-54
pubmed: 20829693
Nervenarzt. 2016 Sep;87(9):989-1010
pubmed: 27439991
J Affect Disord. 2012 Oct;140(2):113-24
pubmed: 22088608
Nervenarzt. 2021 Sep;92(9):925-932
pubmed: 34251504
Dev Psychopathol. 2021 Dec;33(5):1648-1664
pubmed: 34311802
J Psychiatr Res. 2021 Oct;142:226-239
pubmed: 34388482
Neurosci Biobehav Rev. 2011 Jan;35(3):537-55
pubmed: 20603146
Psychol Med. 2017 Mar;47(4):730-743
pubmed: 27869064
Int J Psychophysiol. 2015 Nov;98(2 Pt 2):227-239
pubmed: 25655926
Psychol Bull. 2016 Sep;142(9):991-1015
pubmed: 27416140
Psychopharmacology (Berl). 2015 Jan;232(2):331-41
pubmed: 24973896
Psicol Reflex Crit. 2019 Jul 22;32(1):15
pubmed: 32027006
Acta Psychiatr Scand. 2017 Oct;136(4):352-361
pubmed: 28767127
Lancet Psychiatry. 2016 May;3(5):472-80
pubmed: 27150382
World Psychiatry. 2019 Jun;18(2):192-207
pubmed: 31059629
Psychol Rep. 1997 Apr;80(2):443-6
pubmed: 9129364
Depress Anxiety. 2017 Jan;34(1):9-24
pubmed: 27653321
Depress Anxiety. 2014 Mar;31(3):233-49
pubmed: 24151118
World J Biol Psychiatry. 2015 Oct;16(7):448-71
pubmed: 24635551
Am J Geriatr Psychiatry. 2016 Apr;24(4):320-6
pubmed: 26905044
Clin Psychol Rev. 2007 Apr;27(3):348-65
pubmed: 17222490
Pharmacopsychiatry. 1994 Jul;27 Suppl 1:7-10
pubmed: 7984706
J Abnorm Psychol. 2015 Nov;124(4):933-43
pubmed: 26372005
Depress Anxiety. 2017 Aug;34(8):742-751
pubmed: 28543958
Eur Arch Psychiatry Clin Neurosci. 2023 Apr;273(3):527-539
pubmed: 35778521
Bipolar Disord. 2013 Jun;15(4):422-33
pubmed: 23656284
Am J Psychiatry. 2007 Oct;164(10):1476-88
pubmed: 17898336
Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
pubmed: 2848472
Psychol Bull. 2007 Jan;133(1):1-24
pubmed: 17201568
Neuropsychopharmacology. 2010 Jan;35(1):169-91
pubmed: 19625997
J Anxiety Disord. 2010 May;24(4):403-8
pubmed: 20207102
J Affect Disord. 2008 Feb;106(1-2):1-27
pubmed: 17707915
Clin Psychol Rev. 2019 Aug;72:101756
pubmed: 31351312
Am J Psychiatry. 2012 Jul;169(7):693-703
pubmed: 22535198
Neuropsychopharmacology. 2004 Oct;29(10):1765-81
pubmed: 15213704
Clin Psychol Sci. 2014 Nov 1;2(6):740-747
pubmed: 25419499
Dialogues Clin Neurosci. 2020 Mar;22(1):81-85
pubmed: 32699508
Clin Psychol Rev. 2014 Jul;34(5):417-27
pubmed: 25006008
Curr Top Behav Neurosci. 2016;27:411-49
pubmed: 26026289
Biol Mood Anxiety Disord. 2013 Apr 02;3:7
pubmed: 23547713